Vaccines and Treatments Driving the Pertussis Market Growth 2025

Vaccines and Treatments Driving the Pertussis Market Growth 2025–2034

Pertussis Market Overview: Trends, Treatments, and Future Outlook

The Pertussis Market is poised for steady growth, fueled by increasing awareness of the disease and advancements in effective interventions. Also known as whooping cough, pertussis is a severe respiratory infection caused by Bordetella pertussis. With its multi-stage progression—catarrhal, paroxysmal, and convalescent—early diagnosis and timely treatment remain critical.

Understanding Pertussis Diagnosis and Treatment

Accurate diagnosis of pertussis can be challenging. Techniques such as culture, PCR, paired sera, and single sera tests are commonly used, with paired sera tests considered the most reliable. Prevention remains the most effective approach. Vaccination programs, particularly DTaP and Tdap, are widely implemented in the U.S., recommending at least three doses for adolescents and adults.

When it comes to treatment, macrolide antibiotics like erythromycin, clarithromycin, and azithromycin are standard. However, side effects can sometimes limit patient adherence. Supportive care—including oxygen therapy, hydration, and minimizing respiratory irritants—is also essential.

Pertussis Epidemiology and Market Size

According to DelveInsight’s report, “Pertussis Market Insights, Epidemiology, and Market Forecast – 2034”, approximately 19 million individuals in the U.S. were vaccinated in 2022, with 5 million adults receiving booster doses. Across the seven major markets (7MM), around 34 million people were vaccinated the same year. This number is expected to grow steadily, driven by updated immunization guidelines, increasing awareness, and the introduction of innovative vaccines.

The total Pertussis Treatment Market size in the 7MM was estimated at $3.5 billion in 2022, with the U.S. contributing the largest share.

Vaccine Landscape and Emerging Therapies

Key vaccines driving the Pertussis Therapeutics Market include:

ADACEL (Sanofi Pasteur): A trivalent booster targeting pertussis, tetanus, and diphtheria, available in 55 countries.
BOOSTRIX (GSK): Recommended for individuals aged 10 and above, including maternal immunization programs.

Emerging vaccines under development are gaining attention:

BPZE1 (ILiAD Biotechnologies): An intranasal booster in Phase IIb with FDA Fast Track designation.
BK1310/MT-2355 (Mitsubishi Tanabe Pharma): A 5-in-1 combination vaccine planned for launch in Japan in FY2023.

Market Outlook and Competitive Landscape

Maintaining complete immunization is crucial to controlling pertussis. While infant and childhood vaccination rates are high, adult booster compliance remains low. The Pertussis Drugs Market in the U.S. and Europe is highly competitive, with vaccines like PEDIARIX, PENTACEL, and Vaxelis leading dynamics. In Japan, Mitsubishi dominates with TETRABIK.

The report also highlights pipeline development, collaborations, patent filings, and regulatory progress, offering stakeholders actionable insights. Furthermore, expert opinions, reimbursement scenarios, and competitive intelligence provide a comprehensive view of the Pertussis Companies shaping the market.